ClinicalTrials.gg
RecruitingNCT07508488Updated Jul 10, 2026

Deucravacitinib in the Treatment of Cicatricial Alopecias

A Phase 2 interventional study of Deucravacitinib in Central Centrifugal Cicatricial Alopecia and Frontal Fibrosing Alopecia, sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Icahn School of Medicine at Mount Sinai · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 217 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.

Planned enrollment
152nd of 204
20 · median 40
Started
2026
with 14 others
Phase 2
48 of 217
7 open now
Primary completion
2028-06
later than 58 of 62 live
Registered
206th of 217
by date
Lead sponsor
5 of 217
Icahn School of Medicine at Mount Sinai

Among the 217 studies in Alopecia with a site in United States, this one is the 152nd largest by planned enrollment of the 204 interventional ones that give a count, is one of 15 that started in 2026, is one of 48 in phase 2, reaches primary completion later than 58 of the 62 other live ones, and was the 206th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 127 are open to participants now.

Browse Alopecia studies →

Open to participants now

43 of the 217 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:

37 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 47 (63%) stop at 75 or younger; 10 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 217 studies in Alopecia with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, open-label clinical trial, in which all participants will be treated with deucravacitinib for 48 weeks. Approximately 20 participants will be enrolled: 10 Central Centrifugal Cicatricial Alopecia (CCCA) and 10 Frontal Fibrosing Alopecia (FFA). The study will take place at the Icahn School of Medicine at Mount Sinai (ISMMS). At the Baseline/Day 0 visit, participants will initiate treatment with deucravacitinib. All participants will receive deucravacitinib 12mg once-daily for 48 weeks. The treatment period will conclude at week 48.

03

Conditions studied

  • Central Centrifugal Cicatricial Alopecia
  • Frontal Fibrosing Alopecia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants of any gender, age 18 years or older, at the time of at Screening
  • Participants who are willing and able to adhere to the study visit schedule and comply with protocol requirements.
  • Participant self-reports a history of at least 6 months of moderate-to-severe CA (FFA or CCCA). Diagnosis will be made clinically, and severity assessed with according to the FFASI32 ≥30 and/or CHLG ≥3.
  • Participant has a negative Tuberculin purified protein derivative (PPD) or QuantiFERON TB-Gold test (QFT) at screening or within the last 12 months.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of (WOCBP) OR Is a WOCBP (all female participants, regardless of whether or not they have experienced/reported menarche, are considered WOCBP unless they are permanently sterile or confirmed infertile). A WOCBP who is sexually active must use a method that is highly effective, with a failure rate of \<1%, during the intervention period and for at least 28 days after the last dose of study intervention. And if a WOCBP, must have a negative highly sensitive serum pregnancy test at the screening visit and a negative urine pregnancy test at baseline performed before the first dose of study intervention.
  • Participant is judged to be in otherwise good overall health following a detailed medical and medication history, physical examination, and laboratory testing.

Exclusion criteria

Exclusion Criteria:

  • Participant's cause of hair loss is indeterminable and/or they have concomitant causes of alopecia, such pregnancy-related, drug-induced, telogen effluvium, or advanced androgenetic alopecia.
  • Participant has a history of CA for > 5 years since the disease onset, severe fibrosing disease, or very rapid hair loss at screening.
  • Participant has a history of moderate to severe keloids on the scalp, as determined by clinical examination at screening. Deucravacitinib in the Treatment of Cicatricial Alopecias October 23, 2025.
  • Other scalp disease that may impact assessment (e.g., scalp psoriasis, dermatitis, etc.).
  • Participant is pregnant or breastfeeding.
  • Participation in other studies involving drug(s) within 4 weeks or within 5 half-lives (if known), whichever is longer, prior to study entry and/or during study participation (de novo patients only).
  • Active systemic diseases that may cause hair loss (e.g., systemic lupus erythematosus, thyroiditis, systemic sclerosis, etc.).
  • Any Psychiatric condition in the opinion of the investigator precludes participation in the study.
  • Current or recent history of severe, progressive, or uncontrolled renal (including but not limited to active renal disease or recent kidney stones), hepatic, hematological, gastrointestinal, metabolic, endocrine (particularly thyroid disease which can be associated with hair loss), pulmonary, cardiovascular, psychiatric, immunologic/rheumatologic or neurologic disease; or have any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, or interfere with the interpretation of study results; or in the opinion of the investigator, the participant is inappropriate for entry into this study, or unwilling/unable to comply with STUDY PROCEDURES.
  • History of thromboembolic events including DVT and PE or history of inherited coagulopathies.
  • Any present or history of malignancies with the exception of adequately treated or excised non- basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.
  • History of any lymphoproliferative disorder such as Epstein Barr Virus (EBV) related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease.
  • History (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent (more than one episode of) localized, dermatomal herpes zoster.
  • History of systemic infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator within 6 months prior to Day 0.
  • Active acute or chronic infection requiring treatment with oral antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to Day 0 or superficial skin infection within 1 week prior to Day 0. Deucravacitinib in the Treatment of Cicatricial Alopecias October 23, 2025.
  • Considered in imminent need for surgery or with elective surgery scheduled to occur during the study.
  • Active , , (HIV), or positive HIV serology at the time of screening.
  • Participant has any uncertain or clinically significant laboratory abnormalities that may affect interpretation of study data or endpoints, as determined by the PI.
  • Have an active history of alcohol or substance abuse within 1 year prior to Day 0.
  • Participant has received a ≤ 6 weeks prior to study screening.
  • History of adverse systemic or allergic reactions to components of study drug.
  • Use of systemic medications, including, but not limited to, cyclosporine, systemic , mycophenolate mofetil, azathioprine, methotrexate, within 8 weeks prior to baseline visit.
  • Use of other non-biologic systemic agent for CA, including, 5α-reductase inhibitors, hydroxychloroquine, or retinoids, within 4 weeks prior to baseline visit.
  • Use of an intralesional corticosteroids or oral JAK inhibitor (tofacitinib, ruxolitinib, or any JAK1/TYK2 product) within 4 weeks prior to the baseline visit.
  • Any previous use of a TYK2 inhibitor.
  • Participant has used topical corticosteroids, and/or tacrolimus, and/or pimecrolimus or cyclosporine within 1 week before the baseline visit.
  • Participant has been previously treated with biological drugs in the last 12 weeks for other indications.
  • Participants previously tested with a positive or indeterminable PPD or QFT result, including participants that completed standard tuberculosis therapy.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Central Centrifugal Cicatricial Alopecia

    Contains individuals diagnosed with Central Centrifugal Cicatricial Alopecia.

    Drug: Deucravacitinib

  • Experimental
    Frontal Fibrosing Alopecia

    Contains individuals diagnosed with Frontal Fibrosing Alopecia.

    Drug: Deucravacitinib

Interventions

06

What researchers measure

Primary outcomes

  1. Changes in IFNγ in CA scalp

    Changes in TH1 markers in Cicatricial Alopecias on the scalp from Baseline to Week 24

    Time frame: Baseline to Week 24

  2. Changes in CCL5 in CA scalp

    Changes in TH1 markers in Cicatricial Alopecias on the scalp from Baseline to Week 24

    Time frame: Baseline to Week 24

  3. Changes in CXCL9 in CA scalp

    Changes in TH1 markers in Cicatricial Alopecias on the scalp from Baseline to Week 24

    Time frame: Baseline to Week 24

  4. Changes in CXCL10 in CA scalp

    Changes in TH1 markers in Cicatricial Alopecias on the scalp from Baseline to Week 24

    Time frame: Baseline to Week 24

  5. Changes in TGFB1/2 in CA scalp

    Changes in biomarkers of fibrosis in Cicatricial Alopecias on the scalp from Baseline to Week 24

    Time frame: Baseline to Week 24

  6. Changes in vimentin in CA scalp

    Changes in biomarkers of fibrosis in Cicatricial Alopecias on the scalp from Baseline to Week 24

    Time frame: Baseline to Week 24

  7. Changes in fibronectin CA scalp

    Changes in biomarkers of fibrosis in Cicatricial Alopecias on the scalp from Baseline to Week 24

    Time frame: Baseline to Week 24

  8. Changes in CTGF in CA scalp

    Changes in biomarkers of fibrosis in Cicatricial Alopecias on the scalp from Baseline to Week 24

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Changes in IFNγ in CA scalp

    Changes in TH1 markers in Cicatricial Alopecias on the scalp from Baseline to Week 24

    Time frame: Week 24 to Week 48

  2. Changes in CCL5 in CA scalp

    Changes in TH1 markers in Cicatricial Alopecias on the scalp from Baseline to Week 24

    Time frame: Week 24 to Week 48

  3. Changes in CXCL9 in CA scalp

    Changes in TH1 markers in Cicatricial Alopecias on the scalp from Baseline to Week 24

    Time frame: Week 24 to Week 48

  4. Changes in CXCL10 in CA scalp

    Changes in TH1 markers in Cicatricial Alopecias on the scalp from Baseline to Week 24

    Time frame: Week 24 to Week 48

  5. Changes in TGFB1/2 in CA scalp

    Changes in biomarkers of fibrosis in Cicatricial Alopecias on the scalp from Baseline to Week 24

    Time frame: Week 24 to Week 48

  6. Changes in vimentin in CA scalp

    Changes in biomarkers of fibrosis in Cicatricial Alopecias on the scalp from Baseline to Week 24

    Time frame: Week 24 to Week 48

  7. Changes in fibronectin CA scalp

    Changes in biomarkers of fibrosis in Cicatricial Alopecias on the scalp from Baseline to Week 24

    Time frame: Week 24 to Week 48

  8. Changes in CTGF in CA scalp

    Changes in biomarkers of fibrosis in Cicatricial Alopecias on the scalp from Baseline to Week 24

    Time frame: Week 24 to Week 48

  9. Change in The Central Hair Loss Grade (CHLG)

    Change in CHLG from baseline at week 24 and week 48. The Central Hair Loss Grade is a clinical measure of severity that uses a 6 points scale (0 no central scalp hair loss, 1 - minimal central scalp hair loss, 2 - clinically evident central scalp hair loss, 3-5 advanced central scalp hair loss).

    Time frame: Baseline to Week 24; Baseline to Week 48

  10. Change in Frontal Fibrosing Alopecia Severity Index (FFASI)

    Change in FFASI from baseline at week 24 and week 48. The Frontal Fibrosis Alopecia Severity Index utilizes clinical images of the entire hairline divided into 4 sections. Score from 1-5, with higher score indicating more severity.

    Time frame: Baseline to Week 24; Baseline to Week 48

  11. Changes in mRNA Levels of CCL5 gene expression in skin biopsies

    Evaluation of how the two skin conditions (CCCA and FFA) present themselves at the microscopic level. The skin samples will be obtained via biopsies. Changes in mRNA Levels of CCL5 gene expression in skin biopsies quantified by normalized Ct values obtained by quantitative real-time PCR assay, measured at baseline and week 24. The unit of the outcome is called Ct value and it represents the number of amplification cycles to reach a level of fluorescence in the experiment. The Ct value is directly associated to the level of expression of a gene

    Time frame: baseline and week 24

  12. Change in Alopecia Areata Quality of Life Index (AA-QLI)

    Change in Alopecia Areata Quality of Life Index (AA-QLI) in week 24 and week 48. The scores range from 0 - 30 with 0 representing no impact to quality of life and 30 representing extremely large impact.

    Time frame: Week 24 and Week 48

  13. Change in Peak Pruritus Numerical Rating Scale (PP-NRS)

    Change in Peak Pruritus Numerical Rating Scale (PP-NRS) at week 24 and week 48. The score ranges from 0 - 10 with 0 representing no itch and 10 representing worse possible itch.

    Time frame: Week 24 and Week 48

  14. Change in hair count per cm2

    Change in number of hairs present in a 1 cm2 area between Baseline to Week 24 and Baseline to Week 48

    Time frame: Baseline to Week 24; Baseline to Week 48

  15. Change in sum of hair width per cm2

    Change in total hair diameter in a 2 cm2 area between Baseline to Week 24 and Baseline to Week 48

    Time frame: Baseline to Week 24; Baseline to Week 48

  16. Change in terminal:vellus ratio

    Change in the ratio of thick pigmented long hair to fine-barely visible hairs between Baseline to Week 24 and Baseline to Week 48

    Time frame: Baseline to Week 24; Baseline to Week 48

  17. Change in average hairs per follicular unit

    Change in hair density in a 1 cm2 area between Baseline to Week 24 and Baseline to Week 48

    Time frame: Baseline to Week 24; Baseline to Week 48

  18. Change in average hair width

    Change in average width of each individual hair between Baseline to Week 24 and Baseline to Week 48

    Time frame: Baseline to Week 24; Baseline to Week 48

  19. Change in follicular units per cm2

    Change in hair density in a 1 cm2 area between Baseline to Week 24 and Baseline to Week 48

    Time frame: Baseline to Week 24; Baseline to Week 48

  20. Change in inter-follicular mean distance

    Change in average gap between hairs using a diagnotic tool called the HairMetrix diagnostic tool that can accurately measure the interfollicular distance between baseline to Week 24 and baseline to Week 48

    Time frame: Baseline to Week 24; Baseline to Week 48

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Results will be analyzed and published as aggregate data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jun 2028, 25 months after the start.

Of 42 phase 2 interventional studies under Alopecia, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's planned 25 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2026
First posted
Apr 2, 2026
StartActual
May 28, 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Sep 30, 2028
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07508488
Responsible party
Benjamin Ungar (Assistant Professor, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Apr 2, 2026
Start date
May 28, 2026
Primary completion
Jun 30, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Jul 10, 2026

Study contacts

Giselle Singer
Contact
giselle.singer@mssm.edu
2122413288
Benjamin Ungar, MD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion